Monday, 31 August 2026European Markets

LHYFE Stock Impressive Rise On Wednesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with lhyfe (lhyfe.pa) jumping 15.76% to €5.40 on wednesday while cac 40 fell 0.27% to €7,656.75.

lhyfe's last close was €4.66, 50.43% under its 52-week high of €9.40.

about lhyfe

lhyfe sa, a renewable energy company, designs, installs, and operates green hydrogen production units in france. the company operates 93 projects. it serves local authorities, industries, transport and logistics, and fuel distribution. the company was founded in 2017 and is headquartered in nantes, france.

earnings per share

as for profitability, lhyfe has a trailing twelve months eps of €-0.47.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -21.12%.

revenue growth

year-on-year quarterly revenue growth grew by 39.7%, now sitting on 680k for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lhyfe's stock is considered to be oversold (<=20).

yearly top and bottom value

lhyfe's stock is valued at €5.40 at 21:35 est, way below its 52-week high of €9.40 and way higher than its 52-week low of €2.83.

volume

today's last reported volume for lhyfe is 136096 which is 370.88% above its average volume of 28902.

more news about lhyfe (lhyfe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com